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Abstract
Insulin secretion plays a critical role in glucose homeostasis, and failure to secrete sufficient
insulin is a hallmark of type 2 diabetes. Genome-wide association studies (GWAS) have identified
loci contributing to insulin processing and secretion1,2; however, a substantial fraction of the
genetic contribution remains undefined. To examine low-frequency (minor allele frequency
(MAF) 0.5% to 5%) and rare (MAF<0.5%) nonsynonymous variants, we analyzed exome array
data in 8,229 non-diabetic Finnish males. We identified low-frequency coding variants associated
with fasting proinsulin levels at the SGSM2 and MADD GWAS loci and three novel genes with
low-frequency variants associated with fasting proinsulin or insulinogenic index: TBC1D30,
KANK1, and PAM. We also demonstrate that the interpretation of single-variant and gene-based
tests needs to consider the effects of noncoding SNPs nearby and megabases (Mb) away. This
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study demonstrates that exome array genotyping is a valuable approach to identify low-frequency
variants that contribute to complex traits.
Exome sequencing studies have discovered many low-frequency and rare coding variants3
that have yet to be examined systematically for association with complex traits. To
determine the role of low-frequency coding variants in traits reflecting pancreatic beta-cell
function, insulin sensitivity, and glycemia, we evaluated putative functional coding variants
selected from exome sequences of >12,000 individuals (see Online Methods for a
description of exome array design and content). We successfully genotyped 9,660 Finnish
participants in the population-based Metabolic Syndrome in Men (METSIM) study4 for
247,870 variants on the Illumina HumanExome Beadchip. Clinical characteristics of 8,229
analyzed non-diabetic study participants are summarized in Supplementary Table 1. Among
242,071 variants passing quality control, 89,864 (38.1%) were variable in the studied
individuals; of these, 71,077 were nonsynonymous, nonsense, or located in splice sites
(Supplementary Table 2). We tested 59,029 variants with MAF>0.05% for association with
insulin processing, secretion, and glycemic traits assuming additive allelic effects and using
a linear mixed model to account for relatedness among study participants5.
We first evaluated rare and low-frequency coding variants at the nine signals previously
identified by GWAS for fasting proinsulin level adjusted for fasting insulin (hereafter
referred to as fasting proinsulin)1. To recognize independent association signals, we carried
out conditional analysis adjusting for the known GWAS variants, all of which were
represented on the exome array and replicated in METSIM (P<.01; Figure 1, Supplementary
Table 3). Coding low-frequency variants at the known SGSM2 and MADD loci showed
strong evidence of association (P<5×10−8; Table 1, Supplementary Figures 1 and 2).
Previous studies highlighted several possible candidate genes at these loci1,6,7.
At SGSM2, rs61741902 (MAF=1.4%, P=8.9×10−10) encodes Val996Ile and is independent
of GWAS variant rs4790333 (Pcond=4.8×10−10, r2=.001; Table 1, Figure 1, Supplementary
Table 4). SGSM2 (small G protein signaling modulator 2) is a GTPase activating protein
(GAP) that interacts with members of the Rab and Rap small G protein pathways and may
act in a cascade of Rab-mediated steps in insulin secretory vesicle transport8–10. At
rs61741902, the reference valine is well-conserved across vertebrates, and the isoleucine
substitution is predicted to be damaging (Supplementary Table 5) Each additional copy of
the minor allele was associated with an average increase of 0.41 standard deviations (SD) in
fasting proinsulin (Table 1, Supplementary Figure 2). Still, the proportion of the trait
variability explained is modest (0.47%; 95% CI = 0.22–0.82%) due to the low minor allele
frequency. Identification of an independent and plausibly functional variant suggests that
SGSM2 is the causal gene underlying the common fasting proinsulin GWAS signal.
At MADD, rs35233100 (MAF=3.7%, P=7.6×10−15) creates stop codon Arg766Ter and is in
modest linkage disequilibrium (LD) with the lead GWAS variant rs7944584 (Pcond=.0001,
r2=.17), and independent of the second GWAS variant rs1051006 (Pcond=5.0 × 10−16, r2=.
02). The nonsense allele of rs35233100, associated with decreased proinsulin, is observed
only on haplotypes containing the proinsulin-decreasing allele of rs7944584. Adjusting for
one variant in a conditional analysis decreased, but did not eliminate, association for the
other (P=4.9 × 10−25 and Pcond=5.7 × 10−15 for rs7944584; Table 1, Supplementary Table
4), suggesting biological contributions from the nonsense variant and an additional causal
variant tagged by rs7944584. Of note, the trait-decreasing alleles of the two common
GWAS-identified variants rs7944584 and rs1051006 tend to occur on different haplotypes,
causing the evidence of association for either SNP to become dramatically more significant
when adjusting for the other (rs1051006, P=0.033 and Pcond=2.7 × 10−8; rs7944584, P=4.9 ×
10−25 and Pcond=8.3 × 10−31, Supplementary Table 4). Although the conditional association
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for the nonsense variant only achieves suggestive significance (P=.0001), it provides an
especially plausible functional effect. The MADD nonsense variant is located in exon 13 of
36, suggesting that the mRNA would be targeted for nonsense-mediated decay11. MADD
can act as a guanine nucleotide exchange factor for RAB3 proteins including RAB3A and
RAB3B12, which are critical for insulin exocytosis13,14. Identification of a nonsense variant
that contributes to the evidence of association suggests that MADD is a causal gene
underlying the common GWAS signals.
LD at chromosome 11 from 46–57 megabases (Mb) and encompassing MADD has been
reported to extend long distances15. Consistent with this, we noted significant or suggestive
(P<1×10−5) fasting proinsulin association with nonsynonymous variants up to ~9 Mb away
from the lead (noncoding) GWAS variant. Proinsulin-associated variants included rs628524,
located ~9 Mb away and encoding Ser171Asn in the olfactory receptor OR5M11
(P=3.7×10−6 for fasting proinsulin; P as low as 5.0×10−10 for related traits) and rs7941404,
located 376 kb away and encoding Arg349His in AGBL2 (MAF=11.8%; P=4.7×10−21).
After adjusting for the three MADD variants (rs7944584, rs1051006, rs35233100),
association significance for the distant variants was reduced by orders of magnitude
(Supplementary Table 6, Figure 2). The fact that these associations were not eliminated
suggests that additional variant(s) in this region await identification or that we may be
adjusting for imperfect proxies of causal variants. These results also demonstrate that LD
should be considered when interpreting GWAS results in this region. For example, the
recently reported16 novel fasting glucose locus at OR4S1, represented by rs1483121, is in
LD (r2=.19) with the lead and nonsense MADD SNPs ~1 Mb away (Supplementary Table
6).
Next, we tested coding variants across the genome for association with 19 traits measuring
pancreatic beta-cell function, insulin sensitivity, and glucose levels. We identified two genes
harboring low-frequency nonsynonymous variants with novel associations for fasting
proinsulin levels: rs150781447 encoding TBC1D30 Arg279Cys (MAF=2.0%, P=5.5×10−11)
and rs3824420 encoding KANK1 Arg667His (MAF=3.0%, P=1.3×10−8). The TBC1D30
variant was most strongly associated with late-phase proinsulin-to-insulin conversion
(proinsulin AUC30–120; P=1.3×10−16) and the KANK1 variant with early-phase proinsulin-
to-insulin conversion (proinsulin AUC0–30; P=1.6×10−9) (Table 2, Supplementary Figure 1).
The TBC1D30 variant effect is large, with each additional copy of the minor allele resulting
in an average increase of 0.50 SD in proinsulin AUC30–120 (Table 2, Supplementary Figure
2). This variant explained 0.94% of the trait variability (95% CI = 0.55–1.44%). We also
observed a novel locus for insulin secretion as measured by the insulinogenic index,
represented by nonsynonymous SNPs in PAM (smallest P=1.9×10−8) and PPIP5K2, located
200 kb apart, both with MAF=5.3%, and in near-perfect LD (r2=0.997) (Table 2,
Supplementary Figures 1,2, and 3).
Common SNPs at GPSM1, HNF1A, and ABO, previously associated with other traits, are
here associated with insulin secretion or beta-cell function in non-diabetic individuals (Table
2, Supplementary Figure 3). GPSM1 Ser391Leu is in LD with noncoding rs3829109 (r2=.
69), previously associated with fasting glucose2. At ABO, the T allele of rs505922 is a
proxy for the O blood group and has been associated with diverse phenotypes, including
decreased pancreatic cancer risk17 and increased risk for duodenal ulcer18. Near HNF1A,
rs2650000 was previously associated with LDL-cholesterol19 and C-reactive protein20; other
HNF1A variants are associated with MODY3 (MIM #600496) and type 2 diabetes risk21.
TBC1D30 and KANK1 both function in G protein signaling and are strong biological
candidates. TBC1D30 (TBC 1 domain family, member 30) encodes a GAP protein that
likely regulates activity of specific Rab GTPases including RAB3A22 and RAB8A23.
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Rab3A knockout mice show a severe decrease in glucose-induced first phase insulin release
and a 75% decrease in plasma insulin levels, without insulin resistance24. The reference
arginine at rs150781447 is well-conserved across vertebrate species and the cysteine
substitution is predicted to be damaging25 (Supplementary Table 5). The variant is located
within a Rab-GAP domain and within the Kozak sequence of one TBC1D30 isoform and
may alter translation initiation.
KANK1 (KN motif and ankyrin repeat domain-containing protein 1) plays a role in
cytoskeleton formation by regulating actin polymerization26 and negatively regulates Rac1
and RhoA G protein signaling, pathways that have been implicated in insulin secretion27,28.
At rs3824420, the reference arginine is not well conserved across species and the protein
structure is predicted to tolerate the histidine substitution without an effect on function; this
variant may still affect KANK1 or may tag another nearby variant. While rs3824420 has low
frequency in Europeans (MAF=2.9% in Finns), it is common in East Asians (MAF=16%;
Supplementary Table 7).
PAM encodes peptidylglycine alpha-amidating monooxygenase, an essential secretory
granule membrane enzyme that catalyzes α-amidation of peptide hormones such as
proinsulin29. Older mice heterozygous for Pam deficiency exhibit glucose intolerance30. At
rs35658696, the reference aspartic acid is well conserved across vertebrates and located in
one of the catalytic domains, and the glycine substitution is predicted to be damaging
(Supplementary Table 5). The nearby gene PPIP5K2 is involved in cell signaling but has no
known connection to insulin pathways. At rs36046591 in PPIP5K2, in near-perfect LD
(r2=0.997) with rs35658696, the glycine substitution is predicted to be tolerated and the
reference serine is not well conserved across species. This difference suggests that the PAM
variant is causal at that locus, rather than the PPIP5K2 variant, but it is impossible to dissect
them genetically.
Next, we carried out gene-based tests to investigate further the role of rare and low-
frequency variants in insulin secretion and processing. Gene-based tests offer an alternative
to single-variant tests, which are often underpowered to detect association with rare variants.
Tests were performed on trait residuals adjusted for relatedness and covariates (see Online
Methods). To address the impact of less common and rare variants, we considered only
SNPs with MAF<3% or MAF<1%. In total, we tested 10,515 genes having at least two such
variants using the SKAT-O test31.
We found significant associations between fasting proinsulin and TBC1D30, SGSM2, and
ATG13 when using a MAF upper bound of 3% (Table 3, Supplementary Figure 4); by
conditioning on the low-frequency variants detected by single-variant analysis, we
demonstrated that these signals are driven by low-frequency variants. After adjusting for the
common and nonsense variant signals at MADD, significance for ATG13, ~609 kb away,
decreased by orders of magnitude (Table 3), showing that this signal is partially driven by
the MADD variants and suggesting that other variants in this region await identification or
that we may be adjusting for imperfect proxies of the causal variant. No additional
associations were detected with other traits, including type 2 diabetes (data not shown).
In summary, we identified two low-frequency coding variants in genes at known loci and
three novel genes with low-frequency variants associated with insulin processing or
secretion. At least four of these genes play roles in G-protein signaling (Supplementary
Figure 5). We show that the interpretation of both single-variant and gene-based tests needs
to consider the effects of distant common SNPs, an especially important consideration when
exome sequence data are analyzed without data on the surrounding noncoding regions.
Although regions of long-range LD are unusual, at least 24 have been reported15 to extend
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>1 Mb in Europeans, a distance frequently used to claim independence of association signals
in GWAS meta-analyses. Several of the identified exome array variants are plausibly
functional, although ~25% and ~28% of low-frequency nonsynonymous variants on the
exome array were annotated as conserved and plausibly damaging, respectively
(Supplementary Table 2), and the exome array does not provide complete coverage of all
functional variants at each locus. By the content of the exome array, this study was also
limited in its ability to look at very rare variants. While sequencing will still be required to
completely assess variants associated with insulin processing, secretion, and glycemic traits,
this study provides proof-of-principle that exome array genotyping is a powerful approach to




We attempted exome array genotyping of 9,717 participants in the Metabolic Syndrome in
Men (METSIM) study4. Male study participants were randomly selected from the
population register of Kuopio, Eastern Finland (population 95,000). Participants undertook a
1-day outpatient visit to the Clinical Research Unit at the University of Kuopio. Participants
with diagnosed type 1 diabetes or type 2 diabetes (previously diagnosed, on diabetes
medication, with fasting glucose ≥ 7 mmol/l, or with 2-hour glucose ≥ 11.1 mmol/l) were
excluded from quantitative trait analysis. Clinical characteristics of non-diabetic study
participants are provided in Supplementary Table 1. The study was approved by the ethics
committee of the University of Kuopio and Kuopio University Hospital; informed consent
was obtained from all study participants.
OGTT and laboratory measurements
Clinical testing was performed following a 12-h overnight fast. A 2-h oral 75 g glucose
tolerance test (OGTT) was performed with blood samples drawn at 0, 30, and 120 min, for
measurement of plasma proinsulin, insulin, and glucose levels. Plasma specific proinsulin
(Human Proinsulin RIA kit; Linco Research, St. Charles, MO; no cross-reaction with insulin
or C-peptide) and insulin (ADVIA Centaur Insulin IRI, No. 02230141; Siemens Medical
Solutions Diagnostics, Tarrytown, NY; minimal cross-reaction with proinsulin or C-peptide)
were measured by immunoassay, and plasma glucose by enzymatic hexokinase photometric
assay (Konelab System Reagents, Thermo Fisher Scientific, Vantaa, Finland).
Phenotypes
Association results are reported for five traits: fasting proinsulin (adjusted for fasting
insulin), early-phase (ProinsAUC0–30) and late-phase (ProinsAUC30–120) glucose-stimulated
proinsulin-to-insulin conversion measured as proinsulin area under the curve (AUC) during
the first 30 min and remaining 90 min of an OGTT, insulin secretion assessed by the
insulinogenic index32, and a disposition index measure of β-cell compensation for insulin
resistance defined as InsAUC0–30/GluAUC0–30 × Matsuda index of insulin sensitivity
(Matsuda ISI)4,33. The reported associations were discovered by analyzing a total of 19
traits. Other measures of β-cell function included: oral glucose-stimulated proinsulin-to-
insulin conversion during the first 30 min (ProinsAUC0–30/InsAUC0–30), and 30–120 min
(ProinsAUC30–120/InsAUC30–120) of the OGTT, unadjusted fasting proinsulin, fasting
proinsulin/insulin ratio, HOMA-β34, fasting insulin, insulin at 120 min, insulin AUC during
the first 30 min (InsAUC0–30) and during 30–120 min (InsAUC30–120), and early-phase
glucose-stimulated insulin release (InsAUC0–30/GluAUC0–30) adjusted for Matsuda ISI35.
Indices of insulin sensitivity included HOMA-IR34 and the Matsuda ISI36. Associations
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with fasting and 120 min glucose were also tested. Supplementary Figure 6 shows
correlations among traits. We calculated AUC measures using the trapezoid rule.
Exome array
The Illumina HumanExome-12v1_A Beadchip includes 247,870 markers focused on
protein-altering variants selected from >12,000 exome and genome sequences representing
multiple ethnicities and complex traits. Nonsynonymous variants had to be observed three or
more times in at least two studies, splicing and stop-altering variants two or more times in at
least two studies. Additional array content includes variants associated with complex traits
in previous GWAS, HLA tags, ancestry informative markers, markers for identity-by-
descent estimation, and random synonymous SNPs. Details about SNP content and selection
strategies can be found at the exome array design webpage (see URLs).
Genotyping and quality control
9,717 study samples, 104 blind duplicate samples, and 116 HapMap samples of different
ethnicities were genotyped at the Genetic Resources Core Facility (GRCF) at the Johns
Hopkins Institute of Genetic Medicine. Genotype calling was carried out using Illumina's
GenTrain version 1.0 clustering algorithm in GenomeStudio version 2011.1. Cluster
boundaries were determined using study samples. After clustering, 5,574 non-autosomal and
3,379 autosomal variants identified through filtering strategies developed at GRCF were
manually reviewed and clusters edited as necessary. After technical failure and marker-level
quality control, 242,458 of 247,870 (97.8%) attempted markers were successfully genotyped
and had call rate >95% (average call rate 99.95%).
We evaluated genotyping quality using concordance rates for HapMap samples genotyped in
our study and (a) sequenced by Complete Genomics or the 1000 Genomes Project (on-target
regions of integrated phase 1 release; see URLs) or (b) genotyped on the Illumina
HumanOmni2.5 Beadchip by the 1000 Genomes Project. These comparisons were based on
60,574, 117,063, and 39,056 overlapping variants and 17, 49, and 86 individuals,
respectively. Overall concordance rates were 99.933%, 99.972%, and 99.956% for
Complete Genomics and 1000 Genomes sequence data, and HumanOmni2.5 Beadchip data,
respectively. Considering the external data as truth, concordance rates for homozygous
genotypes were 99.982%, 99.987%, and 99.974%, and for heterozygous genotypes were
99.678%, 99.529% and 99.886%, respectively.
In total, 9,660 of 9,717 (99.4%) individuals were successfully genotyped (call rate > 98%).
For the 242,458 SNPs that passed quality control, genotype concordance among the 104
blind duplicate sample pairs was 99.998%. Three sex-mismatched individuals were
identified and excluded from subsequent analyses. One individual per pair of 6 known twin
pairs and 6 unexplained apparent duplicates were excluded.
We carried out principal components analysis (PCA) twice, once excluding HapMap
samples to identify population outliers, and then including HapMap samples to help interpret
outliers. To avoid artifactual results due to family relatedness37, we computed principal
components using SNP loadings estimated from a subset of 7,304 not-close-relatives. We
defined close relatives as ones for whom estimated genome-wide identical-by-descent (IBD)
proportion of alleles shared was >0.10. We estimated IBD sharing using PLINK's "--
genome" option38 and carried out PCA using SMARTPCA37 on a linkage-disequilibrium-
pruned set of 22,464 autosomal SNPs obtained by removing large scale high-LD
regions15,39, SNPs with a MAF < 0.01, or SNPs with HWE P value < 10−6, and carrying out
LD pruning using the PLINK option: "--indep-pairwise 50 5 0.2". Inspecting the first 10
PCs, we identified 12 population outliers, 9 of whom had self-reported non-Finnish
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ancestry; we excluded these 12 individuals from subsequent analysis. After further removal
of 25 individuals with diagnosed type 1 diabetes, 1,376 with type 2 diabetes, and 3 with
missing phenotypes, 8,229 individuals remained for quantitative trait analysis.
Statistical analysis
Single-variant analysis—We tested for trait-SNP association assuming an additive
genetic model using a linear mixed model to correct for relatedness using EMMAX5. We
excluded SNPs with MAF < 0.05% or Hardy-Weinberg equilibrium (HWE) P value < 10−6.
To reduce the impact of outliers, we log-transformed traits with skewed distributions and
then Winsorized all traits at 5 standard deviations from the mean. All traits were adjusted for
BMI, age, and age2 prior to association testing. We analyzed both untransformed residuals
and rank-based inverse-normal transformed residuals to assess robustness of association
results to distributional assumptions. Since no appreciable differences were observed
between the two analyses, we report results for untransformed residuals. Finally, we visually
inspected genotype cluster plots and checked HWE P values for all described variants. The
lowest HWE P value for a reported novel associated variant was 0.09.
Population stratification—To correct for population stratification, we modeled
population structure as part of the random effects, indistinguishable from the relatedness
effect5. To investigate residual population stratification, we calculated genomic control
inflation factors40 and inspected quantile-quantile (QQ) plots for test statistics both before
and after removal of established and newly discovered loci (2 Mb segments centered on lead
SNPs) (Supplementary Figure 7).
Conditional analysis—To identify additional association signals after accounting for the
effects of known and newly discovered trait loci, we carried out conditional analyses where
we included the allele count at the lead SNP(s) at the conditioning loci as covariate(s). To
allow discovery of more than two association signals per locus, we used a stepwise
procedure where additional SNPs were added to the model according to their conditional P
value, as programmed in EMMAX5. We estimated LD metrics r2 and D' using 9,633
METSIM individuals who passed genotyping quality control. LD with SNPs not included on
the exome array was determined based on whole-genome sequence data for 1,479 Northern
European individuals.
Gene-based analysis—For gene-based testing we used the SKAT-O31 test which
encompasses burden tests and SKAT41 as special cases. SKAT-O has been shown to
perform well under a range of scenarios, including scenarios in which protective,
deleterious, and null variants are present, and in which a large number of variants are causal
and associated in the same direction31. To account for relatedness, we adopted an approach
similar to GRAMMAR42 by first obtaining trait residuals adjusted for relatedness using
GenABEL43 and then carrying out gene-based testing. We performed analyses using default
weights31 and MAF upper bounds of 1% and 3% for the combination of nonsynonymous,
stop-altering, and splice-site variants. In total, 10,515 genes with at least two variants were
tested. The results of the naive SKAT-O analysis and the analysis adjusted for relatedness
were highly correlated (Supplementary Figure 8). To evaluate whether common or low-
frequency SNPs associated with the trait in the single-variant analysis can account for a
gene-based test signal, we also carried out conditional analyses by including the allele count
at such SNP(s) as covariate(s).
Statistical significance—We declared a single variant-trait association significant if the
nominal P value was < 4.46 × 10−8, corresponding to a Bonferroni correction for 1,121,551
tests (19 phenotypes × 59,029 variants). We declared a gene-based test association
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significant if the nominal P value was < 2.50 × 10−7, corresponding to a Bonferroni
correction for 199,785 tests (19 phenotypes × 10,515 genes).
Annotation
We annotated variants relative to GENCODE version 7 coding transcripts44 using in-house
developed software (unpublished). Amino acid substitution positions are relative to the
canonical UniProt protein sequence45.
URLs
Exome array design, http://genome.sph.umich.edu/wiki/Exome_Chip_Design;
Complete Genomics 69 Genomes Data, http://www.completegenomics.com/public-data/69-
Genomes;






Refer to Web version on PubMed Central for supplementary material.
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Manhattan plot for the fasting proinsulin analysis. Association results of the single-variant
analysis (−log10 P values) are plotted against genomic position (NCBI Build 37). Previously
identified loci are denoted in blue and loci identified by the current study in red. Fasting
proinsulin levels were log-transformed and adjusted for fasting insulin, body mass index,
age, and age2.
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The MADD gene is located in a region of unusually high linkage disequilibrium on
chromosome 11 from 46 to 57 Mb. Regional association results of the single-variant
analysis (−log10 P values) are plotted against genomic position (NCBI Build 37) for fasting
proinsulin before (a) and after (b) adjustment of the lead SNPs for the common GWAS
signals (rs7944584 and rs1051006) and the nonsense variant rs35233100 (MAF 3.7%) at
MADD. Fasting proinsulin levels were log-transformed and adjusted for fasting insulin,
body mass index, age, and age2. The conditioning SNPs are indicated in blue. For clarity,
only a portion of the 11 Mb region and a subset of the genes are shown.
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Table 3
Genes associated with fasting proinsulin identified by gene-based tests of aggregated low-frequency
nonsynonymous variants with MAF < 3%
Gene Number of
Variants
Variants (minor allele counts) P value Conditional
P value
TBC1D30 2 R279C(324), P746L(427) 3.3 × 10−9 .75a
SGSM2 3 Y416C(78), T789P(3), V996I(236) 2.0 × 10−9 .68b
ATG13 7
L5V(20), I131V(1), Q249P(3), R392W(1),
1.8 × 10−8
.0055d
L427Q(3), G434R(488), X406G(200)c 37e
Fasting proinsulin was log-transformed and adjusted for fasting insulin, BMI, age, and age2. Residuals were adjusted for relatedness and gene-
based testing was carried out using the SKAT-O test (see Online Methods). This analysis was based on 8,224 participants. Reported associations
were significant after Bonferroni correction for testing 19 traits for 10,515 genes (significance threshold: 2.5 × 10−7).
a
After adjusting for the low-frequency nonsynonymous variant R279C (rs150781447) at TBC1D30 (MAF 2.0%).
b
After adjusting for the low-frequency nonsynonymous variant V996I (rs61741902) at SGSM2 (MAF 1.4%).
c
Annotation relative to a non-canonical (longer) isoform.
d
After adjusting for lead SNPs of common GWAS signals (rs7944584 and rs1051006) and nonsense variant rs35233100 at MADD (MAF 3.7%).
e
After adjusting for the low-frequency nonsynonymous variant G434R (rs35619591) at ATG13 (MAF 3.0%).
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